Cardiovascular disease in patients with spondyloarthropathies.

[1]  F. Guillemin,et al.  TNFalpha antagonist therapy in ankylosing spondylitis and psoriatic arthritis: recommendations of the French Society for Rheumatology. , 2006, Joint, bone, spine : revue du rhumatisme.

[2]  M. Hudson,et al.  Antirheumatic drug use and the risk of acute myocardial infarction. , 2006, Arthritis and rheumatism.

[3]  M. Dougados,et al.  Cardiovascular risk and rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. , 2006, Joint, bone, spine : revue du rhumatisme.

[4]  Kevin R Fontaine,et al.  Risk Factors for Lack of Recent Exercise in Adults With Self-Reported, Professionally Diagnosed Arthritis , 2006, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[5]  D. Buskila,et al.  Cardiovascular manifestations of ankylosing spondylitis , 1987, Clinical Rheumatology.

[6]  R. Kissling,et al.  Ankylosing spondylitis and heart abnormalities: do cardiac conduction disorders, valve regurgitation and diastolic dysfunction occur more often in male patients with diagnosed ankylosing spondylitis for over 15 years than in the normal population? , 2006, Clinical Rheumatology.

[7]  C. Sordet,et al.  Spondylarthrite ankylosante et autres spondylarthropathies , 2005 .

[8]  C. Turesson,et al.  Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. , 2005, The Journal of rheumatology.

[9]  P. Claudepierre.  Spa therapy for ankylosing spondylitis: still useful? , 2005, Joint, bone, spine : revue du rhumatisme.

[10]  Robert Riddell,et al.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. , 2005, The New England journal of medicine.

[11]  Marc A Pfeffer,et al.  Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention , 2005, The New England journal of medicine.

[12]  M. A. van de Laar,et al.  Intermittent rises in plasma homocysteine in patients with rheumatoid arthritis treated with higher dose methotrexate , 2004, Annals of the rheumatic diseases.

[13]  B. Dijkmans,et al.  Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. , 2004, Seminars in arthritis and rheumatism.

[14]  T. Schnitzer,et al.  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial , 2004, The Lancet.

[15]  E. Yeh.  CRP as a mediator of disease. , 2004, Circulation.

[16]  A. Calin,et al.  Predictors of longterm outcome in ankylosing spondylitis. , 2003, The Journal of rheumatology.

[17]  W. White,et al.  Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. , 2002, The American journal of cardiology.

[18]  M. Ward.  Predictors of the progression of functional disability in patients with ankylosing spondylitis. , 2002, The Journal of rheumatology.

[19]  A. Oto,et al.  Echocardiographic Evidence of Cardiac Involvement in Ankylosing Spondylitis , 2002, Clinical Rheumatology.

[20]  G. McColl,et al.  Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? , 2002, Arthritis and rheumatism.

[21]  A. Tajik,et al.  Novel risk factors for atherosclerosis. , 2000, Mayo Clinic proceedings.

[22]  P. Ridker,et al.  C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. , 2000, The New England journal of medicine.

[23]  G. Stucki,et al.  Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review. , 1999, The Journal of rheumatology.

[24]  M. Dougados,et al.  Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. , 1999, The Journal of rheumatology.

[25]  M. Crawford,et al.  Aortic root disease and valve disease associated with ankylosing spondylitis. , 1998, Journal of the American College of Cardiology.

[26]  L. Bergfeldt.  HLA-B27-Associated Cardiac Disease , 1997, Annals of Internal Medicine.

[27]  Arnason Ja,et al.  Transthoracic and transesophageal echocardiographic evaluation of the aortic root and subvalvular structures in ankylosing spondylitis. , 1996 .

[28]  P. Jones,et al.  Smoking and outcome in ankylosing spondylitis. , 1996, Scandinavian journal of rheumatology.

[29]  B. Bresnihan,et al.  Doppler echocardiographic evidence of left ventricular diastolic dysfunction in ankylosing spondylitis. , 1993, The American journal of cardiology.

[30]  Ankylosing Spondylitis,et al.  Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. , 1993, Annals of the rheumatic diseases.

[31]  D. Felson,et al.  A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. , 1993, Archives of internal medicine.

[32]  R. Bahler,et al.  Alterations in cardiac diastolic function in patients with ankylosing spondylitis. , 1992, International journal of cardiology.

[33]  B. Bresnihan,et al.  The heart in ankylosing spondylitis. , 1992, Annals of the rheumatic diseases.

[34]  B. Bresnihan,et al.  Echocardiographic abnormalities in ankylosing spondylitis. , 1992, Annals of the rheumatic diseases.

[35]  A. Shah,et al.  Pericardial changes and left ventricular function in ankylosing spondylitis. , 1987, American heart journal.

[36]  D. Gibson,et al.  THE MYOCARDIUM IN ANKYLOSING SPONDYLITIS A Clinical, Echocardiographic, and Histopathological Study , 1987, The Lancet.

[37]  G. Hughes,et al.  Left ventricular function in patients with ankylosing spondylitis and Reiter's disease. , 1984, European heart journal.

[38]  R. Califf,et al.  Complete heart block in better's syndrome , 1984 .

[39]  A. Calin,et al.  Aortitis in ankylosing spondylitis: early detection of aortic root abnormalities with two dimensional echocardiography. , 1982, The American journal of cardiology.

[40]  I. Kushner,et al.  Survival among patients with ankylosing spondylitis: a life-table analysis. , 1981, The Journal of rheumatology.

[41]  R. Doll,et al.  Mortality among patients with ankylosing spondylitis not given X-ray therapy. , 1977, The New England journal of medicine.

[42]  M. D. Levine.  Letter: Confirmation of antentally detected fetal abnormality. , 1974, Lancet.

[43]  A. Good.  Reiter's disease: a review with special attention to cardiovascular and neurologic sequellae. , 1974, Seminars in arthritis and rheumatism.

[44]  Smythe Ha,et al.  The carditis and aortitis of ankylosing spondylitis. , 1958 .

[45]  M. Wilkinson,et al.  Clinical Features and Course of Ankylosing Spondylitis , 1958, Annals of the rheumatic diseases.